Treatment of cancer cells with TNF-α and trastuzumab results in similar decreases in cell viability as trastuzumab-treated cancer cells co-cultured with T-cells in the high overexpressing HER2 + breast cancer cell lines, BT474 and SKBR3. Here, ERBB2 is linked to breast carcinoma.